Efficacy and safety of SB-728-T in patients with HIV/AIDS.

Trial Profile

Efficacy and safety of SB-728-T in patients with HIV/AIDS.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Jan 2017

At a glance

  • Drugs SB 728 T (Primary)
  • Indications HIV infections
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 06 Jan 2017 According to a Sangamo Therapeutics media release, this trial was originally conducted by Sangamo BioSciences but later on this company's name changed to Sangamo Therapeutics.
    • 21 May 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top